Pfizer recalls some antidepressants after drug mixup

Pfizer recalls some antidepressants after drug mixup
Action taken after pharmacist found a heart drug among Effexor/Venlafaxine, FDA says.

(HealthDay)—Two lots of Pfizer's antidepressant drug Effexor XR (venlafaxine HCl) are being recalled because they may contain capsules of another drug called Tikosyn (dofetilide), which is used to treat heart rhythm disorders.

The also includes one lot of generic Greenstone brand venlafaxine HCl capsules, the U.S. Food and Drug Administration said Friday.

The agency said that unknowingly taking Tikosyn could have serious and potentially fatal consequences.

The recall is for:

  • one lot of 30-count Effexor XR 150-milligram extended-release capsules,
  • one lot of 90-count Effexor XR 150-milligram extended-release capsules,
  • and one lot of 90-count Greenstone venlafaxine HC1 150-milligram extended-release capsules.

The Pfizer drug lot numbers are V130142 and V130140, and have an expiration date of October 2015. The Greenstone lot number is V130014, which has an expiration date of August 2015.

The voluntary recall comes after a pharmacist found that a bottle of Effexor XR contained one capsule of Tikosyn 0.25 milligram, the FDA said.

The agency advises pharmacists to immediately halt sales of the recalled lots of the drugs and notify customers who've been sold the drugs. Patients with the recalled medicines should contact their doctor and/or return them to their pharmacy.

Patients who have been prescribed Effexor XR/Venlafaxine HCl but think they may have mistakenly taken a Tikosyn capsule should immediately contact their doctor or a hospital, Pfizer said.

They should monitor themselves for signs of abnormal heartbeat and seek medical help if they feel faint, become dizzy, or have a fast heartbeat, the maker said.

For more information about the recall, call Pfizer at 1-800-438-1985, Monday to Thursday 9 a.m. to 8 p.m. ET or Friday from 9 a.m. to 5 p.m. ET.

More information: The U.S. Food and Drug Administration has more about Tikosyn.

More Information

add to favorites email to friend print save as pdf

Related Stories

Pfizer will buy NextWave Pharma for up to $700M

Oct 22, 2012

(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.

Drugmaker Ranbaxy halts generic Lipitor production

Nov 30, 2012

Problem-plagued Ranbaxy Pharmaceuticals Inc. has halted production of generic cholesterol drug Lipitor while it investigates how tiny glass particles got into the ingredients used for dozens of batches of the drug that were ...

First generic version of cancer drug Doxil approved

Feb 04, 2013

(HealthDay)—The first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) has been approved by the U.S. Food and Drug Administration, which says the action should help relieve shortages ...

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments